ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Aim Immunotech Inc

Aim Immunotech Inc (0A4Y)

0.00
0.00
(0.00%)
Closed March 29 12:30PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
-
Bid
0.00
Ask
0.00
Volume
4,194
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
Previous Close
0.00
Open
-
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
48,082,000
Dividend Yield
-
PE Ratio
-4.45
Earnings Per Share (EPS)
-0.4
Revenue
141k
Net Profit
-19.45M

About Aim Immunotech Inc

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
1970
Aim Immunotech Inc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker 0A4Y. The last closing price for Aim Immunotech was $0. Over the last year, Aim Immunotech shares have traded in a share price range of $ 0.00 to $ 0.00.

Aim Immunotech currently has 48,082,000 shares outstanding. The market capitalization of Aim Immunotech is $86.55 million. Aim Immunotech has a price to earnings ratio (PE ratio) of -4.45.

0A4Y Latest News

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast OCALA, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- AIM...

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research Data demonstrate...

AIM ImmunoTech Announces Launch of CEO Corner Platform

AIM ImmunoTech Announces Launch of CEO Corner Platform CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties...

AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update

AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update Company continues progress across Ampligen® clinical development programs Growing body of...

AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer

AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of...

AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer

AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer Subject enrollment is expected...

AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer

AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic...

AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DE
40000000DE
120000000DE
260000000DE
520000000DE
1560000000DE
2600000000DE

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

Discussion

View Full Feed
pantherj pantherj 3 minutes ago
Huh?? What in the world does this mean?? "IFUS is a disputer ..."
IFUS
MonopolyTrader MonopolyTrader 3 minutes ago
I can’t get over how bad Jim has fumbled this.. OTC is hot and he keeps his old tactics.. he doesn’t adapt to the new social media days.. just clueless..
GSTC
Nikodemos Nikodemos 3 minutes ago
PLEASE! Don't ever CONFUSE self-interest optics with INTEGRITY.

[] GRAB WOMEN BY THE PUSSY
[] I COULD SHOOT A person on 5th avenue & NOT lose any votes

[] The Bible is my FAVORITE BOOK!!
[] But I can't quote from it

20,000 of CONald's "WALL
DJT
Red_Right_Hand Red_Right_Hand 3 minutes ago
https://ineedmedic.com/health/brain-tumor-vaccines-a-promising-new-frontier-in-glioblastoma-treatment/
NWBO
cjstocksup cjstocksup 4 minutes ago
https://x.com/iamyesyouareno/status/1773675119178580322?s=20
louieforpar louieforpar 4 minutes ago
The sacrilegious, Bible touter buried his ex wife at his golf course solely for the purpose of a tax benefit.








https://www.google.com/url?q=https://www.newsweek.com/donald-trump-ivanas-burial-tax-breakwhat-we-do-know-what-we-dont
DJT
norisknorewards norisknorewards 4 minutes ago
Keep up the daily fud tho chief
NWBO
Genz2 Genz2 4 minutes ago
If AXA was smart in writing its cyber insurance they would make Wave a mandatory element for organizations getting their cyber insurance!!! That way their claims would be nearly non existent and I believe that they may have had some good experience with Wave!! They could make money hand over fist
louieforpar louieforpar 4 minutes ago
With the trial of former Trump attorney, John Eastman, taking place this has resurfaced. I remember it well.

Eric Hershman, former Trump Republican attorney, gave the following advice to Johnny Eastman. Read on see the video hilarious. This is a REPUBLICAN Trump attorney at the time
DJT
moola26 moola26 5 minutes ago
No one selling. Haven’t you got the memo. Majority holding strong.
Step-by-Step Step-by-Step 5 minutes ago
and so the entertainment begins......................
SPZI
HippyTrades HippyTrades 5 minutes ago
Goes to show how uninformed TopPenny is about trading.
Yet he pretends to be retired from trading full time....🤣🤣🤣
PSRU
cjstocksup cjstocksup 5 minutes ago
https://x.com/MattWallace888/status/1773424549964480977?s=20
pantherj pantherj 5 minutes ago
You can repeat your fantasies a thousand times and still there is no proof of them. Show us the proof. Show us the science. 14 years of lies is all you have.
IFUS
cjstocksup cjstocksup 6 minutes ago
https://x.com/VigilantFox/status/1773051037659636154?s=20
crowin crowin 6 minutes ago
My Motto;

Make a Buck and Do Not get Greedy and STUCK.
IGPK
louieforpar louieforpar 6 minutes ago
Facts.

Yes there was charity fraud as evident by the judgement against him.


Charity fraud:

https://www.google.com/url?q=https://www.nytimes.com/2019/12/10/nyregion/trump-foundation-lawsuit-attorney-general.html&sa=U&sqi=2&ved=2ahUKEwiXo_OblaOEA
DJT
awesomed007 awesomed007 6 minutes ago
Help me to understand, if filings are done in April, how quickly does ce removal take, happen? Thanks
CYBL
Dingbatt Dingbatt 6 minutes ago
No MSFT and AMZN are definitely in that class
AMZN MSFT
louieforpar louieforpar 6 minutes ago
That’s MAGA for you when faced with facts. Just like their puppeteer they resort to the call of violence.

Can’t accept facts or defeat.





QUICKLY DEFACED & VANDALIZED!!

Publicly funded restoration, SEE HERE:
https:
DJT
glenn1919 glenn1919 7 minutes ago
bottoms..............................SNAX......GRDI....ZVIA........MULN........https://stockcharts.com/h-sc/ui?s=MULN&p=W&b=5&g=0&id=p84354014936
https://stockcharts.com/h-sc/ui?s=ZVIA&p=W&b=5&g=0&id=p84354014936
https://stockcharts.com/h-sc/ui?s=GRDI&p=W&b=5&g=0&id=p84354014936
GRDI MULN SNAX
louieforpar louieforpar 7 minutes ago
What level headed Americans profess.

The truth!!!!



https://www.google.com/url?q=https://www.yahoo.com/news/larry-david-tees-off-trump-124933350.html&sa=U&sqi=2&ved=2ahUKEwiI2PmTq5eFAxVylIkEHaBQAy8QFnoECCMQAQ&usg=AOvVaw1ahJ-3Q2laQTHZ_Cw1pkDn
DJT

Your Recent History

Delayed Upgrade Clock